CN101765600A - 吡唑并嘧啶酮激酶抑制剂 - Google Patents

吡唑并嘧啶酮激酶抑制剂 Download PDF

Info

Publication number
CN101765600A
CN101765600A CN200880100285A CN200880100285A CN101765600A CN 101765600 A CN101765600 A CN 101765600A CN 200880100285 A CN200880100285 A CN 200880100285A CN 200880100285 A CN200880100285 A CN 200880100285A CN 101765600 A CN101765600 A CN 101765600A
Authority
CN
China
Prior art keywords
compound
individual
cancer
pharmaceutically acceptable
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN200880100285A
Other languages
English (en)
Chinese (zh)
Inventor
亚瑟·F·克鲁格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agennix AG
Original Assignee
GPC Biotech AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GPC Biotech AG filed Critical GPC Biotech AG
Publication of CN101765600A publication Critical patent/CN101765600A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/28—Oxygen atom
    • C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN200880100285A 2007-05-29 2008-05-28 吡唑并嘧啶酮激酶抑制剂 Pending CN101765600A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US93215507P 2007-05-29 2007-05-29
US60/932,155 2007-05-29
EP07113226.0 2007-07-26
EP07113226A EP2019101A1 (en) 2007-07-26 2007-07-26 Pyrazol[3,4-d]pyrimidin-4-one useful as Kinase Inhibitor
PCT/EP2008/056569 WO2008145678A1 (en) 2007-05-29 2008-05-28 Pyrazolopyrimidinone kinase inhibitor

Publications (1)

Publication Number Publication Date
CN101765600A true CN101765600A (zh) 2010-06-30

Family

ID=38556321

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200880100285A Pending CN101765600A (zh) 2007-05-29 2008-05-28 吡唑并嘧啶酮激酶抑制剂

Country Status (19)

Country Link
US (2) US8304418B2 (enExample)
EP (2) EP2019101A1 (enExample)
JP (1) JP2010528088A (enExample)
KR (1) KR20100040806A (enExample)
CN (1) CN101765600A (enExample)
AR (1) AR066737A1 (enExample)
AT (1) ATE522533T1 (enExample)
AU (1) AU2008257534A1 (enExample)
CA (1) CA2689090A1 (enExample)
DK (1) DK2170891T3 (enExample)
EA (1) EA200901536A1 (enExample)
ES (1) ES2370677T3 (enExample)
HR (1) HRP20110768T1 (enExample)
IL (1) IL202375A0 (enExample)
MX (1) MX2009012832A (enExample)
SI (1) SI2170891T1 (enExample)
TW (1) TW200906831A (enExample)
WO (1) WO2008145678A1 (enExample)
ZA (1) ZA200908943B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106458919A (zh) * 2014-05-13 2017-02-22 广东东阳光药业有限公司 一种中间体的制备方法

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2660146T3 (es) * 2009-04-29 2018-03-21 Nerviano Medical Sciences S.R.L. Sales del inhibidor de cdk
WO2013059634A1 (en) 2011-10-20 2013-04-25 The Regents Of The University Of California Use of cdk9 inhibitors to reduce cartilage degradation
US10300073B2 (en) 2014-10-14 2019-05-28 The Regents Of The University Of California Use of CDK9 and BRD4 inhibitors to inhibit inflammation

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US3916889A (en) * 1973-09-28 1975-11-04 Sandoz Ag Patient ventilator apparatus
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US4710384A (en) 1986-07-28 1987-12-01 Avner Rotman Sustained release tablets made from microcapsules
EG18377A (en) 1986-09-19 1993-04-30 Lilly Co Eli Process for preparing glycopeptide antibiotics
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
PT752248E (pt) 1992-11-13 2001-01-31 Idec Pharma Corp Aplicacao terapeutica de anticorpos quimericos e marcados radioactivamente contra antigenios de diferenciacao restrita de linfocitos b humanos para o tratamento do linfoma de celulas b
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US6559152B2 (en) * 1998-10-13 2003-05-06 Dupont Pharmaceuticals Company 6-substituted pyrazolo[3,4-d]pyrimidin-4-ones useful as cyclin dependent kinase inhibitors
US6531477B1 (en) * 1998-10-13 2003-03-11 Dupont Pharmaceuticals Company 6-substituted pyrazolo [3,4-d] pyrimidin-4-ones useful as cyclin dependent kinase inhibitors
EP1156060B1 (en) 2000-05-12 2007-06-27 GPC Biotech AG Human peptides/proteins causing or leading to the killing of cells including lymphoid tumor cells
IT1317975B1 (it) 2000-06-16 2003-07-21 Christian Pio Pedulla Presa multipla volante.
WO2003063764A2 (en) * 2001-07-10 2003-08-07 Bristol-Myers Squibb Pharma Company 6-SUBSTITUTED PYRAZOLO [3,4-d] PYRIMIDIN-4-ONES USEFUL AS CYCLIN DEPENDENT KINASE INHIBITORS
US20050090471A1 (en) * 2001-10-15 2005-04-28 Gpc Biotech, Inc Inhibitors of cyclin-dependent kinases, compositions and uses related thereto
EP1611136A2 (en) * 2003-04-07 2006-01-04 GPC Biotech Inc. Inhibitors of cyclin-dependent kinases, compositions and uses related thereto
US8084457B2 (en) 2003-09-15 2011-12-27 Lead Discovery Center Gmbh Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases
EP1709051A1 (en) 2003-12-23 2006-10-11 GPC Biotech Inc. Inhibitors of cyclin-dependent kinases, compositions and uses related thereto

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106458919A (zh) * 2014-05-13 2017-02-22 广东东阳光药业有限公司 一种中间体的制备方法
CN106458919B (zh) * 2014-05-13 2019-03-15 广东东阳光药业有限公司 一种中间体的制备方法

Also Published As

Publication number Publication date
ZA200908943B (en) 2010-08-25
HRP20110768T1 (hr) 2011-11-30
US20100160350A1 (en) 2010-06-24
AR066737A1 (es) 2009-09-09
SI2170891T1 (sl) 2011-12-30
TW200906831A (en) 2009-02-16
EA200901536A1 (ru) 2010-06-30
ATE522533T1 (de) 2011-09-15
AU2008257534A1 (en) 2008-12-04
EP2170891B1 (en) 2011-08-31
US20130035349A1 (en) 2013-02-07
ES2370677T3 (es) 2011-12-21
WO2008145678A1 (en) 2008-12-04
MX2009012832A (es) 2010-05-17
JP2010528088A (ja) 2010-08-19
KR20100040806A (ko) 2010-04-21
IL202375A0 (en) 2010-06-30
DK2170891T3 (da) 2011-12-12
EP2170891A1 (en) 2010-04-07
EP2019101A1 (en) 2009-01-28
US8304418B2 (en) 2012-11-06
CA2689090A1 (en) 2008-12-04

Similar Documents

Publication Publication Date Title
US8518958B2 (en) Pyrido [2,3-D] pyrimidines and their use as kinase inhibitors
JP7215687B2 (ja) キナーゼ阻害活性を有する化合物、その製造方法及び用途
EP2112150B1 (en) Improved raf inhibitors
RU2548363C2 (ru) СЕЛЕКТИВНЫЕ ИНГИБИТОРЫ Haspin киназы
US20140163223A1 (en) Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors
TW200948813A (en) Plk inhibitors
US20200165239A1 (en) Protein kinase inhibitors, preparation method and medical use thereof
WO2004043936A1 (ja) Ｐｌｋ阻害剤
WO2008150260A1 (en) 8-oxy-2-aminopyrido (2, 3-d) pyrimidin-7-one derivatives as kinase inhibitors and anticancer agents
US20130035349A1 (en) Pyrazolopyrimidinone kinase inhibitor
EP2719696A1 (en) Novel kinase inhibitors
EP2325185A1 (en) Plk inhibitor
US8232283B2 (en) Raf inhibitors
EP1674457B1 (en) Derivatives of squaric acid with anti-proliferative activity
JP7186874B2 (ja) ピラゾリル化合物およびその使用方法
HK1137985B (en) Improved raf inhibitors
HK1135974A (en) Derivatives of squaric acid with anti-proliferative activity
TW201043630A (en) Purine derivatives and anticancer agent using the same

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20100630